Elios Therapeutics Reports 24-Month Survival Data for Personalized Vaccine

Nov 21, 2019

|

NEW YORK – Elios Therapeutics reported 24-month survival data from a trial investigating its tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with advanced, resected melanoma.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Elios Therapeutics Reports 24-Month Survival Data for Personalized Vaccine

To read the full story....

Breaking News

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

Featured White Papers

What's Popular?

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors

Blueprint Medicines Advance Pralsetinib in Multiple RET-Mutant Indications

Phase I Study of Novel Drug Shows Preliminary Activity in Mesothelin-Expressing Tumors

Sponsorships